Morton Judith, Glanville Allan R
Department of Respiratory and Sleep Medicine, Monash Medical Center, Clayton, Victoria, Australia.
Semin Respir Crit Care Med. 2009 Oct;30(5):559-68. doi: 10.1055/s-0029-1238914. Epub 2009 Sep 16.
Cystic fibrosis is one of the most common indications for lung transplantation worldwide and certainly the most common indication for all pediatric lung transplants and for bilateral lung transplantation irrespective of age. Outcomes are outstanding when compared with other indications for lung transplantation, and an increasing number of centers now report mean survival of greater than 10 years posttransplant. Hence it is important to concentrate on the broad panoply of potential systemic complications of cystic fibrosis and address proactively issues that may be associated with adverse outcomes. Optimum management of infectious, nutritional, diabetic, renal, bone, and gut complications is critical to long-term success so that recipients may realize their full potential. Timing of referral for consideration of active listing should allow sufficient time for the patient and lung transplant team to develop a productive working relationship based on best available evidence and mutual trust, which will culminate in a long-term successful outcome.
囊性纤维化是全球肺移植最常见的适应证之一,无疑也是所有儿童肺移植以及无论年龄的双侧肺移植最常见的适应证。与肺移植的其他适应证相比,其预后非常出色,现在越来越多的中心报告移植后平均生存期超过10年。因此,重要的是要关注囊性纤维化潜在的广泛全身并发症,并积极解决可能与不良预后相关的问题。对感染、营养、糖尿病、肾脏、骨骼和肠道并发症进行最佳管理对于长期成功至关重要,以便受者能够充分发挥其潜力。考虑主动列入等待名单的转诊时机应使患者和肺移植团队有足够时间基于现有最佳证据和相互信任建立富有成效的工作关系,这将最终带来长期的成功结果。